GRAND RAPIDS, Mich.

密歇根州大急流城

,

，

Aug. 18, 2026

2026年8月18日

/PRNewswire/ -- Capitan Orthopedics, Inc. (

/美通社/ -- Capitan Orthopedics, Inc.（

https://capitanortho.com/

https://capitanortho.com/

) announced today that it has closed its oversubscribed Seed round, bringing its total capital raised to date to $4.1 million.

）今日宣布，其超额认购的种子轮融资已圆满结束，迄今累计融资总额达410万美元。

Chance W. Leonard, CEO of Capitan Orthopedics, Inc., commented, 'I am extremely excited to announce that we have not only closed our Seed round, but have oversubscribed by over $1.1 million dollars. In addition to our recent receipt of FDA Breakthrough Device Designation, our team continues to reach milestone achievements at an accelerated pace.

Capitan Orthopedics, Inc. 首席执行官 Chance W. Leonard 表示：“我非常激动地宣布，我们不仅完成了种子轮融资，而且超额认购超过110万美元。除了最近获得美国食品药品监督管理局（FDA）的突破性设备认定外，我们的团队还在以更快的速度不断实现里程碑式的成就。”

Today is yet another special day in our rapidly progressing project timeline.'.

今天是我们快速推进的项目时间轴上又一个特殊的日子。

Capitan Orthopedics, Inc. intends to use the funds to continue its project development and validation efforts and begin its first in-human clinical trial, which is expected to begin in Q1 2027.

Capitan Orthopedics, Inc. 计划利用这笔资金继续推进其项目开发和验证工作，并启动首次人体临床试验，预计该试验将于2027年第一季度开始。

Mr. Leonard also added, 'We remain very encouraged by our continued progress on this innovative project, the strength of the unmet clinical need and the unique opportunity it creates. Our investors clearly recognize this opportunity, and their capital investment demonstrates significant confidence in the work we are doing.

莱昂纳德先生还补充道：“我们对该创新项目持续取得的进展、未满足临床需求的迫切性，以及由此带来的独特机遇，依然深感鼓舞。我们的投资者显然认可这一机遇，他们的资本投入彰显了对我们所开展工作的高度信心。”

The progress we are making to deliver to the market a solution that is simple, reproducible, and cost effective is exceptional. With core development complete and a clear regulatory path ahead, we look forward to beginning our first in human clinical trial as soon as possible.'.

我们在向市场提供一种简单、可重复且具成本效益的解决方案方面取得了非凡进展。随着核心开发工作完成以及监管路径清晰明朗，我们期待尽快启动首次人体临床试验。

R. Sean Churchill, MD, MBA, shoulder reconstruction specialist, and surgeon design team member, 'For decades surgeons have struggled with the irreparable rotator cuff tear. For those patients 65 years and older, the reverse total shoulder arthroplasty provides outstanding results. However, for the younger, active patients with an irreparable rotator cuff tear, there remains a void in surgical treatment options.

医学博士、工商管理硕士 R. Sean Churchill 是肩关节重建专家及外科医生设计团队成员，他表示：“数十年来，外科医生一直在为不可修复的肩袖撕裂问题而困扰。对于65岁及以上的患者，反向全肩关节置换术能够提供卓越的疗效。然而，对于患有不可修复肩袖撕裂的年轻活跃患者，手术治疗选择方面仍存在空白。”

The SupraSpacer™ stands to fill that gap with a durable, metallic implant that maintains the humeral head aligned with the glenoid throughout a full shoulder range of motion while preserving 90% of the humeral head cartilage. The seven-step surgical procedure is straightforward, reproducible, and ideal for utilization in the ambulatory surgery center.'.

SupraSpacer™ 旨在通过一种耐用的金属植入物填补这一空白，该植入物在保留90%肱骨头软骨的同时，能在肩关节全范围活动过程中保持肱骨头与关节盂的对齐。其七步手术操作简便、可重复性强，非常适用于门诊手术中心。

About Capitan Orthopedics, Inc.

关于卡皮坦骨科公司

Capitan Orthopedics, Inc. is an innovator in the design of orthopedic implant products for shoulder surgery. The company has developed the SupraSpacer™ implant and procedure to successfully address the critical unmet need of irreparable rotator cuff tears in younger, active patients. This novel technology fills a distinct gap in the current care continuum and provides surgeons with a simple, reproducible solution that integrates smoothly into existing surgical workflows.

Capitan Orthopedics, Inc. 是肩关节手术骨科植入物产品设计领域的创新者。该公司开发了 SupraSpacer™ 植入物及相关手术方案，以成功满足年轻活跃患者中不可修复性肩袖撕裂这一关键且未获充分解决的临床需求。这项新颖技术填补了当前诊疗体系中的显著空白，为外科医生提供了一种简单、可重复的解决方案，并能无缝融入现有的手术工作流程。

The system is purpose-built for the ASC setting and includes sterile-packaged instruments and implants to support procedural efficiency. .

该系统专为门诊手术中心（ASC）环境量身打造，配有无菌包装的器械和植入物，以提升手术效率。

Capitan Orthopedics, Inc. is backed by Genesis Innovation Group, Inc. (

Capitan Orthopedics, Inc. 由 Genesis Innovation Group, Inc. 支持（

https://genesisinnovationgroup.com/

https://genesisinnovationgroup.com/

), a leader in medical device development and commercialization and represents a compelling opportunity to bring a first-in-class solution to a large, underserved patient population. For investment information, please contact the company at 1-833-444-2468.

），作为医疗器械开发与商业化领域的领导者，代表了将首创疗法带给庞大且未获充分满足的患者群体的极具吸引力的机遇。如需获取投资信息，请通过 1-833-444-2468 联系该公司。

https://genesisinnovationgroup.com

https://genesisinnovationgroup.com

https://capitanortho.com

https://capitanortho.com

SOURCE Capitan Orthopedics, Inc.

来源：Capitan 骨科公司

21

二十一

%

%

more press release views with

更多新闻稿浏览量，借助

Request a Demo

申请演示